Aduro Biotech is a clinical-stage cancer immunotherapy company with multiple therapeutic approaches in development that have the potential to yield powerful immunotherapy combinations.
Aduro Biotech – engineered Immunotherapy for Cancer
Aduro’s novel technologies are in development to induce highly targeted, potent and sustained immune responses against a variety of cancers. Aduro Biotech has three diverse immunotherapy platforms – LADD (live, attenuated, double-deleted Listeria mononcytogenes), CDNs (cyclic dinucleotides) and B-select antibodies (B-select), alone or in combination. Promising initial clinical trial results led Aduro to initiate the Phase 2b ECLIPSE trial, a combination of its lead product candidate, CRS-207, and GVAX Pancreas, in patients with metastatic pancreatic cancer. CRS-207 is the first candidate to emerge from Aduro’s proprietary LADD platform.
Aduro Biotech is a biopharma company headquartered in Berkeley (USA). Board of Directors is composed by Stephen Isaacs, Gerald Chan, William Greenman, Ross Haghighat, Frank McCormick, Stephanie Monaghan O’Brien and Stephen Sherwin. Aduro recently acquired BioNovion BV, a premier antibody discovery and development company located in the Netherlands. BioNovion is now a subsidiary of Aduro and will operate under the name of Aduro Biotech Europe. This addition secures a unique position for Aduro in the immuno-oncology field as a company with multiple therapeutic approaches that have the potential to yield powerful immunotherapy combinations under one umbrella. Aduro Biotech also has collaborations with academia, pharmaceutical and biotechnology companies to explore its technologies as single agents or in combination with other novel or standard of care agents in other cancers including glioblastoma, non-small cell lung cancer, prostate cancer and ovarian cancer.
More about Aduro Biotech : www.aduro.com